Edwards Retires Its Favorite Word Just as the Market Starts Believing It

Edwards Lifesciences closed its third quarter with the kind of numbers that normally end an argument. Sales of $1.72 billion grew 11.2%; TAVR delivered $1.2 billion, up 8.8%; TMTT jumped 45.6% to $207 million; Surgical added 3% to $264 million. Adjusted EPS came in at $0.80 and full-year guidance went up, not sideways: total company sales growth to approximately 11.5%, adjusted EPS to $2.97–$3.05 for 18% growth at the midpoint, and TAVR from the 6–8% frame management was defending in February to 9–9.5%.

The more revealing moment, though, was a demotion. On the same call where he raised the TAVR guide, CEO Bernard Zovighian told investors the engine underneath it is changing: “we are assuming that growth will be mainly driven by continued increases in procedure volume and less by share gains” — Bernard J. Zovighian, Chief Executive Officer · 2026-11-04. When Vijay Kumar of Evercore asked why a company about to hold the broadest TAVR label — severe symptomatic, asymptomatic, and pending moderate — wouldn't simply keep taking share, the answer was almost apologetic: “we are not going to push for it” — Bernard J. Zovighian, Chief Executive Officer · 2026-11-04.

The Lever Changes Hands

This is not a small rhetorical shift; it closes a book that had run for more than a year. In February, Dan Lippis was explicit that “the share gain that we had from the Boston Scientific exit contributed a big chunk of that” — Daniel Lippis, Global Leader (likely VP or General Manager, Structural Heart) · 2026-02-10 gap between high-single-digit procedural growth and reported TAVR growth. In July, Robbie Marcus of JPMorgan was still framing the beat as market expansion plus competitive wins. By this week, Lippis had converted all of it into arithmetic that has run out:

We've had multiple quarters, more than 4 quarters of year-over-year benefit, but that's now fully annualized... we've also observed 4 quarters of modest share gains... the last 2 quarters, we're seeing sequential stability there.

Which produces a nice inversion in the language data. share gain is the single highest-ranked keyword in Edwards' own Q3 set — ranked first, as it was last quarter — and it is being used to describe something being retired. Into its place step market growth and procedure growth, the words that now have to carry the mid-to-high-single-digit long-term TAVR target on their own. Analysts heard the implication immediately, and three of them in a row tried to get a 2027 number out of management. All three were sent to the December 4 Investor Conference.

I'm not signaling... that a slowdown or whatsoever. I'm signaling confidence and I'm signaling a difference in mix.

Worth noting: the phrase heightened focus — used again this quarter to describe the clinical community's attention to TAVR — has been in management's vocabulary since at least the start of the year. The demand signal is real; the novelty of the language is thinner than the tone suggests.

Moderate: A Category-Sized Claim Without a Date

The genuinely new material is PROGRESS. The trial, presented at TCT and published in the New England Journal of Medicine, is being sold not as an incremental label but as a change in how aortic stenosis is managed. Lippis framed the sizing without picking a side: “the moderate patient population is 1 to 2 times bigger than the severe population, or you can look at it through the lens that the severe population is 2 to 3 times bigger than what we thought it was” — Daniel J. Lippis, Corporate Vice President – TAVR · 2026-11-04. Bernard went further, arguing the moderate patient opportunity is at least as large as severe — and the supporting ACTIVATE registry data (53,000+ patients) says moderate cases outnumber severe nearly 2 to 1, with ~80% carrying at least one at-risk feature.

The keyword flows confirm the emphasis: MODERATE is far and away the biggest mover in Edwards' own keyword impact history this quarter, alongside proactive disease management, a theme that has been climbing since early 2026 and has now been handed the actual commercial weapon — a modernized CMS national coverage determination covering asymptomatic patients and creating a MAC pathway for future indications.

What was not provided is a date. Lippis declined to discuss FDA conversations, offering only that a broader update on moderate timing would come “in a few weeks at investor conference” — Daniel J. Lippis, Corporate Vice President – TAVR · 2026-11-04, and Bernard conceded the coverage tailwind will be “a gradual impact, you know, progressive impact year over year” — Bernard J. Zovighian, Chief Executive Officer · 2026-11-04. Compare that with February, when the NCD was described as “negligible” — Daniel Lippis, Global Leader (likely VP or General Manager, Structural Heart) · 2026-02-10 for 2026 and more relevant in 2027 and beyond, and July, when PROGRESS impact was “minimal” — Bernard Zovighian, Chief Executive Officer · 2026-07-23 for this year. The catalyst has arrived; the calendar has not.

The Beat's Ingredient List

New CFO Doretta Mistras — on her first full year in the seat — delivered the raise alongside an honest accounting of where the earnings came from. Adjusted gross margin of 78.7% beat last year's 77.9% on manufacturing efficiencies and a 50bp FX tailwind, and adjusted operating margin hit 30.3%. But the fourth quarter is guided to a mid-20s operating margin, and the EPS beat itself was helped by “our planned phasing of strategic investments in R&D and SG&A throughout the year” — Doretta Mistras, Chief Financial Officer · 2026-11-04. R&D was flat year over year at $281 million, dropping from 18.1% to 16.4% of sales. The GAAP series tells the same story: R&D has slipped to roughly 16% of a $1.7 billion revenue base.

The balance sheet remains a weapon: effective net cash of about $5.0 billion, roughly $700 million of repurchases through Q3, and $1.3 billion left on the authorization.

Why the Tape Is Only Half-Awake

The shares are up 9.8% over the last 90 trading days — a calm, grinding advance into the print — yet still sit 24% below the December 2021 peak of $130.68. The multiple has done the heavy lifting in reverse: 8.0x price-to-revenue, roughly 48% below the 2021Q4 peak of 15.5x. This is a de-rated compounder printing a guidance raise, not a broken story finding religion.

It also remains a purely company-unique tale. Across twelve quarters of market-wide top-75 keyword sets, structural heart never appears; the global conversation has been tariffs, AI data centers, fuel costs, and Middle East conflict. Edwards is not riding a wave — it is the wave. The instructive contrast is the adjacent cardiac-device theme of Pulsed Field Ablation, a persistent global advancer with a visible catalyst curve, where the tape has already voted enthusiastically. TAVR indication expansion has the clinical evidence, the coverage decision, and five new therapy approvals this quarter — what it lacks is a dated revenue ramp the market can underwrite.

That is exactly what December 4 is for. The questions to hold management to: does the moderate submission get a date; does the 2027 TAVR frame land at or above the mid-to-high-single-digit long-term target now that share is retired as a lever; and does the promised 50–100bp of annual operating margin expansion survive a step-up in R&D that a company claiming a new disease category should probably be funding more aggressively. Edwards has spent years arguing that evidence moves practice slowly. It now has to prove that a slower-moving, market-led growth model is worth the multiple it once commanded.